Expand XENE Menu
XENE MENU

XENE Latest Press Releases

-- May 29, 2026 --

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- May 7, 2026 --

Xenon Reports Q1 2026 Financial Results and Provides Business Update Globe Newswire 4:01 PM

-- May 1, 2026 --

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- April 30, 2026 --

Xenon to Report Q1 2026 Financial Results on May 7, 2026 Globe Newswire 4:01 PM

-- April 19, 2026 --

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting Globe Newswire 6:00 PM

-- April 15, 2026 --

Xenon to Present at Upcoming Investor Conferences Globe Newswire 8:30 AM

-- April 7, 2026 --

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting Globe Newswire 8:30 AM

-- March 12, 2026 --

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares Globe Newswire 4:01 PM

-- March 10, 2026 --

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering Globe Newswire 10:39 PM

-- March 9, 2026 --

Xenon Pharmaceuticals Announces Proposed Public Offering Globe Newswire 4:01 PM
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) Globe Newswire 7:00 AM

-- March 8, 2026 --

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 Globe Newswire 2:00 PM

-- February 26, 2026 --

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes